In the past two decades, further advances in treatment have been achieved with the introduction of biological therapies, such as belimumab, a monoclonal antibody against B cell activating factor belonging to the tumour necrosis factor (TNF) ligand family (BAFF), and anifrolumab that binds the type I IFN receptor, both approved for treating SLE, as well as the anti-CD20 agent rituximab that is used off-label in refractory cases (9). Here, TNFSF13B is linked to systemic lupus erythematosus.